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ABSTRACT 
PROVIDER BASED INTERVENTIONS TO MITIGATE RISK FOR  
OPIOID PAIN MEDICATION ABUSE AMONG ADULT  
PATIENTS IN A PRIMARY CARE SETTING 
by Sheree Lamara Conley-Donaldson 
May 2017 
Mental and substance use disorders are predicted to exceed all physical disease 
processes causing major disability by 2020. Misuse and overdose of opioid pain 
medications is a significant public health concern in the United States. Approximately 1 
in 4 patients receiving prescription opioids in primary care settings struggle with misuse. 
Half of all opioid prescriptions are written by primary care providers, including nurse 
practitioners. The purpose of this DNP project was to determine if nurse practitioner 
providers are implementing evidence-based practice guidelines including screening, brief 
intervention, and referral to treatment (SBIRT) to mitigate risk of prescription opioid pain 
medication misuse and abuse among patients who request a prescription for opioid pain 
medication. Nurse practitioner providers were instructed on current evidence-based 
opioid guidelines to include conducting a comprehensive assessment and screening for 
opioid misuse/abuse, brief intervention, and referral for behavioral health/addiction 
services treatment based on risk level scoring. There was a total of 9 out of 12 or 75% of 
patients age 18-25 that presented requesting an opioid pain medication. There was an 
even sex distribution, including 6 males (50%) and 6 females (50%). After implementing 
screening, brief intervention, and treatment, eight (66%) patients were identified as low 
risk; two (17%) patients were identified as moderate risk, and 2 (17%) patients were 
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identified as high risk for opioid abuse. The two (17%) patients identified as high risk 
received brief intervention and were referred for treatment. This project identified the risk 
level for opioid pain medication misuse/abuse. Implementing evidence-based guidelines 
for prescribing opioid pain medications and SBIRT in the clinical setting conjunctly with 
other validated screening tools could prove to be quite effective in combating 
misuse/abuse of opioid pain medication based on results of the project. 
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CHAPTER I - INTRODUCTION 
Mental and substance use disorders are predicted to exceed all physical disease 
processes causing major disability by 2020 (Crowley & Kirschner, 2015).  A drastic 
increase in prevalence of opioid use disorder (OUD) has been linked to an increase in 
opioid pain medication prescriptions (Centers for Disease Control and Prevention [CDC], 
2016).  In 2013, 249 million prescriptions for opioids were written by healthcare 
providers to treat chronic pain (CDC, 2016).  Individuals that are prescribed opioids for 
chronic pain are at risk for misuse, abuse, addiction, overdose, and death if they take 
opioid pain medications for nonmedical reasons (Katz, El-Gabalawy, Keyes, Martins, & 
Sareen, 2013). Nonmedical prescription opioid use (NMPOU) leads to adverse health 
outcomes and has thereby become a major public health concern (CDC, 2016).  There are 
mental and physical factors which may be used to predict OUD.  Researchers found 
prevalence of OUD in patients with comorbid mental disorders and physical conditions 
(Katz et al., 2013). 
Patients at risk for misuse and overdose of prescription opioid pain medications 
frequent primary care settings. Half of all opioid prescriptions are written by primary care 
providers, including nurse practitioners.  Safe prescribing practice models for chronic 
pain management have been developed for prescribing opioids (CDC, 2016; Hudspeth, 
2016a; Hudspeth, 2016b). Approximately one in four patients receiving prescription 
opioid pain medications in primary care settings struggle with misuse.  Routine screening 
for anxiety/depression and substance use disorders in primary care settings is imperative 
to mitigate the risk for adverse health outcomes (CDC, 2016).  This project focuses on 
identification and prevention of opioid use disorder, through screening and referral for 
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treatment, in patients requesting a prescription opioid pain medication in a primary care 
clinic. 
Background 
Misuse and overdose of opioid pain medications is a major public health concern 
in the United States (U.S.). Approximately 1 in 4 patients receiving prescription opioids 
in primary care settings struggle with misuse of opioid pain medication.  More than 40 
people die from prescription opioid overdoses per day (CDC, 2016).  Greater than 
165,000 deaths from overdose related to prescription opioids have occurred since 1999 
and more than 14,000 individuals died in 2014 alone (CDC, 2016). 
Significance 
Cost of Opioid Misuse  
Misuse and abuse of prescription pain medication alone has cost the nation around 
$53.4 billion annually in lost productivity, medical costs, and criminal justice costs.  
Health care dollars are being allocated for prevention and treatment of opioid use 
disorder.  Reimbursement will be determined by implementing new measures including 
tracking of high-dose opioid use from four or more providers and pharmacies by non-
cancer patients using the prescription monitoring program (PMP) (CMS, 2015).  
Medicare uses PMP to track opioid prescribers.  A new strategy is being developed to 
report physicians who may be prescribing opioids inappropriately.  Centers for Medicare 
and Medicaid Services (CMS) has launched an attack on the opioid epidemic (CMS, 
2017a).  The Medicare population has the one of the highest and fastest growing rates of 
OUD.  This is concluded to be due to no systemic policy of screening for opioid misuse.  
State and national initiatives related to healthcare quality and cost include exploring the 
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possibility of supporting and strengthening primary care in efforts to improve quality and 
reduce costs.  The CMS strategy includes four priority areas.  Prescribers are advised to 
(1) implement more effective person-centered strategies to reduce risk of misuse and (2) 
expand screening, diagnosis, and treatment of OUD.  Practitioners are also encouraged to 
(3) increase the use of evidence-based practices for acute and chronic pain management.  
Improper prescribing is a contributory factor to misuse and overdose of opioid pain 
medications; (4) naloxone use, distribute, and access should be expanded when clinically 
necessary (CMS, 2017a).    
Governmental agencies are combining forces to combat the problem of opioid 
prescription drug overdose.  The aim is to prevent misuse, treat dependence and 
ultimately save lives.  The extent of the problem has progressed from local and regional 
perspectives to a national awareness.  The United States Food and Drug Administration 
(FDA) (2012) has joined the effort to decrease prescription opioid misuse.  Public health 
officials are collaborating with prescribers, state and local partners to ensure safe use and 
disposal of opioid medications.  In February 2016, the FDA received a citizen petition 
from several local and state public health officials in addition to other stakeholders 
requesting changes to existing labeling for opioid analgesics.  The FDA supports stronger 
warning labels and misuse deterrents (FDA, 2016).  Opioid warning labels require boxed 
warnings, which are the FDA’s strongest warning.  The labels note that opioids carry 
serious risks of misuse and abuse, addiction, overdose and even death (CDC, 2016). 
Chronic Pain  
The International Association for the Study of Pain (IASP) (2016) defines chronic 
pain as pain which persists beyond three months (p. 11).  Millions of United States 
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citizens, one-third of the population, in fact, are affected by chronic pain. Chronic pain 
prevalence in the United States (US) is estimated to be greater than 30 million citizens. 
Around 25 million of these individuals have moderate to severe pain.   Chronic pain has 
been shown to be greatly comorbid with other medical conditions (IASP, 2016).   
The burden of dealing with chronic pain can diminish a patient’s psychological 
well-being.  The ability to maintain gainful employment, relationships with significant 
others, and social activities may be limited; this can result in feelings of anxiety or 
depression.  Daily activity and quality of life are significantly lowered.  Consequently, 
Americans receive disability insurance primarily for pain.  Stigma can also result from 
patient encounters with healthcare providers who are not properly trained in the 
management of chronic pain.  Evidence reveals 40% to 70% of persons with chronic pain 
are not receiving adequate medical treatment.  Concerns for both over and under treating 
in this population have been raised (IASP, 2016). 
 An estimated 5 to 8 million Americans use opioids for long-term management of 
their chronic pain.  Long-term, defined as greater than three months, opioid therapy for 
chronic pain in adult patients is associated with increased risk of misuse and overdose. 
Consequently, higher doses are associated with higher risks (Chou et al, 2015).  While 
some patients experience significant pain relief from opioids without adverse effects, 
benefits and risks must be weighed.  Many problems have been caused by the vast 
number of opioids prescribed leading to their illicit use by the public (Reuben et al, 
2015).  
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Opioid Pain Medications 
 Prescription opioids are very potent pain medications and include oxycodone, 
hydrocodone, and morphine among others (U.S. Food and Drug Administration, 2016).  
Prescription opioid pain medications are used for severe pain, can have serious side 
effects if not used correctly, and are often misused by patients.  Patients may take higher 
doses than prescribed to experience a state of euphoria and patients may also divert 
medications to friends or relatives (McDonald & Carlson, 2013).   
Opioid pain medications are scheduled drugs, or controlled substances, which are 
regulated by the Food and Drug Administration.  Scheduling classes are in place to 
prevent misuse and abuse.  Schedule I controlled substances are not used in medical 
settings in the U.S.  Schedule II has accepted medical use.  Schedule II controlled 
substances have a high potential for abuse and require a written and signed prescription 
that may not be refilled.  Examples of Schedule II opioid prescription medications are 
fentanyl, hydrocodone, methadone, and oxycodone.  Most commonly abused opioids are 
hydrocodone and oxycodone (U.S. Food and Drug Administration [FDA], 2016).  
Schedule III substances may lead to moderate physical dependence or high psychological 
dependence.  Buprenorphine is a Schedule III opioid substance used for medication-
assisted treatment (MAT) of OUD.  Schedules IV and V have the lowest abuse potential.   
Next, there are two main categories of opioid pain medications—immediate 
release (IR) and extended-release/long-acting (ER/LA).  IR are the most often prescribed 
type of opioid and is used for breakthrough pain.  ER/LA are opioids used for prevention 
of baseline pain by maintaining a constant level of drug for 8-72 hours. The FDA (2012) 
approved a Risk Evaluation and Mitigation Strategy (REMS) for ER and LA opioid 
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medications. REMS is a strategy to allow patient access to ER/LA opioid pain 
medications through safe prescribing and reduction and management of risks for adverse 
patient outcomes. Inappropriate prescribing leads to risk for misuse and abuse and 
potential serious adverse patient outcomes including addiction, unintentional overdose, 
and death (FDA, 2012, 2016). 
Table 1  
Opioid Controlled Substance Schedules I-V 
Schedule I 
No accepted 
medical use in 
US 
Schedule II 
Codeine 
Fentanyl 
Hydrocodone 
Meperidine 
*Methadone 
Morphine 
Oxycodone 
 
 
Schedule III 
*Buprenorphine 
Schedule IV 
No opioids 
identified in 
this class 
Schedule V 
Codeine (not 
more than 
200mg/100 ml) 
and opium 
preparations 
(not more than 
100 mg/100 
mg or ml) 
Note: *Used in medication-assisted treatment (MAT) of Opioid Use Disorder (OUD) 
Opioid Misuse, Abuse and Addiction 
Misuse involves the use of prescription medication in a way which is against 
directions (American College of Preventive Medicine, 2016).   Misuse can be grouped 
into several categories:   
• Not taking the medication as prescribed 
• Bingeing 
• Injecting, crushing, snorting 
• Diversion 
• Aggressive behavior 
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The American College of Preventive Medicine (2016) states abuse is self-
administration to alter one’s state of consciousness or to “get high.”  Moreover, addiction 
is a primary, chronic, neurobiological disease, with genetic, psychological, and 
environmental factors.  Addiction is characterized by 4 C’s impaired control, compulsive 
use, continued use despite harm and craving (American College of Preventive Medicine, 
2016). Tolerance and withdrawal are signs of physical dependence.  Tolerance is defined 
as a reduction in effect requiring increased dosages to produce desired effect.  
Withdrawal symptoms to assess for are rapid heartbeat, agitation, insomnia, diarrhea, 
sweating, and runny nose (Paone, Dowell, & Heller, 2011). 
Self-medication describes use of a drug without consulting a healthcare 
professional to alleviate stressors or disorders such as depression and anxiety (Shapiro, 
Coffa, & McCance-Katz, 2013).  Non-medical use is intentional or unintentional use of 
legitimately prescribed medication in an un-prescribed manner for its psychic effect.  
Individuals also often share their unused opioid prescription pain medications, unaware 
of the dangers of nonmedical prescription opioid use (NMPOU).  NMPOU leads to abuse 
and addiction characteristic of OUD (CMS, 2016). 
Opioid Use Disorder (OUD)  
The Diagnostic and Statistical Manual for Mental Disorders (DSM-5) states 
substance use disorder is evident when the repetitive use of alcohol and/or drugs causes 
debilitation and failure to carry out activities of daily living involving home, school, or 
work.  For opioid use disorder, specifically, 2 of 11 criteria must be met over a 12-month 
period (APA, 2013).  Criteria include: 
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(1) individuals with OUD often take opioids in larger amounts or over longer periods of 
time than prescribed;   
(2) they may possess a strong desire or have failed efforts to control opioid use; activities 
to obtain, use or recover from opioids is carried out; 
(3) individuals experience craving or urge to use opioids;  
(4) recurrent opioid use results in a failure to fulfill major role obligations;  
(5) there is continued opioid use despite problems;  
(6) important tasks are given up;  
(7) physical hazards are posed due to use; 
(8) individuals with OUD persistently use opioids even with knowledge of physical or 
psychological complications caused by the substance; 
(9) tolerance is reached; and  
(10) withdrawal symptoms manifest.  (American Psychiatric Association, 2013).   
OUD has had an impact on special populations—adolescents, women, and 
individuals ages 16-45.  Through research efforts, misuse of prescription drugs has been 
shown to affect young adults most, especially age 18 to 45 (CDC, 2016). In 2014, 
467,000 adolescents were current nonmedical users of opioid prescription pain 
medications, with 168,000 having an addiction (CDC, 2016).  Women are more like to 
have chronic pain and may become more dependent on prescription opioids more quickly 
than men leading to OUD.  Between 1999 and 2010, 48,000 women died of prescription 
pain reliever overdoses (CDC, 2016).  Patients that request prescription opioid pain 
medications from primary care providers must be evaluated for risk of opioid pain 
medication misuse/abuse.  Screening for risk of opioid pain medication misuse/abuse 
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may alert providers of possible opioid use disorder and help stratify patients per risk 
level. 
Prescribing   
Primary care providers (PCPs), including nurse practitioners (NPs), manage 
chronic pain and prescribe opioid pain medications. Currently, 49 of 50 states allow NPs 
to prescribe controlled substances, including opioid pain medication.  Nurse practitioners 
may be granted controlled substances prescriptive authority through the state board of 
nursing.   Prescribing habits correlate with misuse, and misuse leads to problematic 
opioid-related behavior including opioid use disorder (OUD) and accidental overdose; 
therefore, screening for risk for misuse, abuse, and OUD prior to prescribing opioid pain 
medications is recommended (CMS, 2017a).  
Screening   
Mitigation strategies to prevent OUD involve screening and lack thereof results in 
missed treatment opportunities (Bowman, Eiserman, Beletsky, Stancliff, & Bruce, 2013).  
The Opioid Risk Tool (ORT) is a self-reported screening tool utilized with patients 16 
years of age and older in primary care settings to assess risk for opioid abuse (National 
Institute of Drug Abuse, 2015).  Patients with high risk have increased likelihood of 
opioid use disorder and may require referral for treatment.    
Needs Assessment 
State Level 
The state of Mississippi is a leading prescriber of prescription opioid pain 
medication, ranked 5th in prescribing opioids nationally. In 2012, an equivalent of 1.2 
opioid prescriptions for each citizen were prescribed (Mississippi State Department of 
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Health, 2016).  Hydrocodone is the most commonly prescribed opioid in Mississippi.  In 
July 2016, 145,846 prescriptions equal to 8,343,259 dosage units were written (MSDH, 
2016).  Mississippi has the 30th highest national unintentional drug overdose mortality 
rate (Levi, Segal, & Miller, 2013). 
All providers are required to use the Mississippi prescription drug monitoring 
program (PMP) when prescribing controlled substances (Mississippi Board of Medical 
Licensure [MBOML], 2013: Mississippi State Board of Nursing [MSBN], 2016) to 
decrease the number of opioid pain medications prescribed and unintentional drug 
overdose. The PMP tracks the number of drug units prescribed, the number of providers 
prescribing controlled substances for a patient, and the pharmacies used by the patient to 
fill prescriptions for controlled substances.  In the state of Mississippi, NPs have 
prescriptive authority after meeting all MSBN requirements and may prescribe any 
schedule of controlled substance after completion of 720 hours of monitored practice and 
registration with the U.S. Drug Enforcement Agency (DEA) (MSBN, 2016). The MSBN 
monitors inappropriate opioid prescribing practices by APRN with CSPA.   
Local Level  
While working as a family nurse practitioner (FNP) in the internal medicine 
department of a primary care clinic, several patients have presented with complaints of 
chronic pain.  These patients request prescriptions for opioid pain medications often 
reporting allergies to or ineffectiveness of non-opioid pain medications.  Similar 
encounters have been verbalized by other providers including physicians and nurse 
practitioners.  Each provider expressed lack of discernment with this group of patients. 
As a student in a Doctor of Nursing Practice (DNP) degree program, completion of a 
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DNP project is a requirement for the degree. In my role as a nurse practitioner provider at 
the primary care clinic and project director for this DNP project, a needs assessment of 
the recognized practice problem was conducted to determine the extent of the problem in 
the clinical practice setting. A chart review was conducted in collaboration with 
executive staff and members of the internet technology (IT) department in efforts to 
gauge an estimate of patients currently being treated for pain-related diagnoses.  A 
retrospective review of the previous 30 calendar days revealed a total of 66 initial and 
established patient encounters with a diagnosis of chronic pain and documentation of 
prescribing an opioid pain medication.  There were 32 (48%) males and 34 (52%) 
females identified in the chart review and twenty-six (39%) patients were between the 
ages of 16-45.  The most common ICD 10 diagnoses were M54.5 (low back pain) and 
M79.7 (fibromyalgia).  Only 20 (30%) patients seen were prescribed an opioid. Seven 
(11%) patients had a history of substance-related disorders with no documentation of a 
risk assessment performed.  The majority of the patients 45 (68%) were seen by NPs. 
 Misuse of prescribed opioid pain medication is a problem pertinent to primary 
care.  Misuse may be prevented through proper prescribing consistent with evidence-base 
practice recommendations for conducting a comprehensive assessment that includes 
screening for risk of opioid pain medication abuse/misuse (CMS, 2017a).  This DNP 
project explores the PICOT question: “In patients 18-45 years of age, who present to a 
primary care clinic requesting a prescription for opioid pain medication, will screening by 
nurse practitioners identify patients at risk for opioid abuse leading to appropriate 
intervention or referral?” 
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 The DNP project will focus on nurse practitioner providers in a designated 
federally qualified health center (FQHC) and patient-centered medical home (PCMH) 
primary care clinic in southeastern Mississippi.  A FQHC is an organization which 
qualifies for enhanced reimbursement from Medicare and Medicaid (CMS, 2017b).   A 
PCMH is a model in which treatment is facilitated by primary care providers to 
coordinate needed care (NCQI, 2017). This DNP project will ask the question; find the 
evidence; appraise; act; evaluate and reflect (Schaffer, Sandau, & Diedrick, 2013) to 
ensure mitigation of risks related to opioid abuse.  Proposed mitigation strategies include 
NPs implementing an opioid abuse/misuse risk assessment screening tool in practice and 
providing evidence-based interventions and referrals to hopefully, prevent OUD. 
Outcomes extend beyond improved patient outcomes but also hopefully, promote better 
prescribing practices by NP providers, and decreased health care costs.   
Relevant Review of the Literature 
 Databases accessed for this review of literature include CINAHL, MEDLINE, 
PsycARTICLES, and evidence-based treatment guidelines.  Key terms used in the review 
of literature were chronic pain, evidence-based practice, risk mitigation strategies, 
identification, opioid pain medication, opioid use disorder, abuse, misuse, prevention, 
primary care, and screening.  The proposed aim of this DNP project is to determine if 
nurse practitioners in a primary care setting are implementing evidence-based practice 
guidelines to mitigate risk of prescription opioid pain medication abuse among patients 
who request a prescription for opioid pain medication.  
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Management Strategies  
 In March 2016, the Centers for Disease Control and Prevention released 
guidelines to provide recommendations for providers who prescribe opioid pain 
medications.  The guidelines are not intended for chronic pain related to active cancer 
treatment, palliative care, and end of life care.  Initiation, selection, dosage, duration, 
follow-up, discontinuation, assessing risk and addressing harms of opioid use are 
addressed through twelve recommendations.   
•  Non-pharmacologic treatment is preferred.  If pharmacologic treatment is 
warranted, non-opioid treatment should be initiated with or without opioid 
pharmacologic therapy as appropriate.  
• Providers should establish treatment goals with each patient prior to initiation 
of treatment.  Goals for pain and function should be realistic.  If there is 
clinically significant improvement in pain and function which outweighs risks 
to patient safety, opioids may be continued.  
• Known risks should be discussed with all patients prior to starting therapy as 
well as periodically.  Patient and provider responsibilities should be outlined 
(CDC, 2016).   
• Immediate-release opioids should be prescribed when starting therapy instead 
of extending release/long-acting opioids.   
• Lowest effective dose should be prescribed at start.   
• No greater quantity than necessary for the anticipated duration of severe pain 
should be prescribed.  Three days or less will often suffice.  Rarely, greater 
than seven days is needed for acute pain (CDC, 2016).  
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• Benefits and harms should be evaluated within the first four weeks especially 
before dose escalation.  The goal is to taper opioids to lower doses or 
discontinue all together is deemed safe.  
• Consideration of offering naloxone is indicated for patients with increased risk 
of overdose such as a history of substance use disorder; higher opioid dosages; 
concurrent benzodiazepine use; or history of overdose.   
• Providers should review patients’ Prescription Monitoring Program (PMP) 
when starting opioid pain medications and periodically during treatment for 
chronic pain (CDC, 2016).   
• Use of urine drug testing is also recommended when starting opioid pain 
medications as well as periodically during treatment, at least annually.   
• Clinicians should avoid prescribing opioid pain medication to patients 
currently taking benzodiazepines.   
• Providers should offer or arrange evidence-based treatment for patients with 
opioid use disorder (CDC, 2016). 
The American Pain Society (APS) and the American Academy of Pain Medicine 
(AAPM) comprised a panel to develop an evidence-based guideline on chronic opioid 
therapy (COT) for individuals with chronic pain (Chou et al., 2009).  The investigators 
reviewed 8,034 abstracts.  A total of 14 systematic reviews and 57 primary studies were 
included in the report of evidence.  The expert panel recommends clinicians first obtain 
appropriate diagnostic tests for evaluation of any underlying conditions.  Consideration of 
the effectiveness of non-opioid therapy should precede COT.  Reliable evidence on 
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methods to assess potential benefits of COT is limited.  Screening tools for the 
assessment of potential risks of COT are helpful for risk stratification.  More validation 
studies are needed however to explore outcomes.  The ORT has been shown to have 
construct partial validity.  The strongest factor predictive of drug misuse after initiation of 
COT is a personal or family history of alcohol or drug abuse.  Patients should receive 
informed consent and participate in their opioid manage plans.  Initiation and titration of 
COT follow.  An initial trial typically lasts from several weeks to several months.  
Proceeding beyond this time frame warrants careful consideration of trial outcomes.  
Clinicians should monitor and reassess patients on COT periodically.  Urine drug screens, 
as well as other information to determine adherence, are useful, but quality of evidence 
regarding these measures is low as well.  When pain is accompanied by comorbidities, 
clinicians should integrate or refer for therapies that target psychosocial factors.  
Cognitive-behavioral therapy is consistently shown to be effective for chronic pain.  
Functional restoration and specific behavioral interventions in addition to pain education 
have been shown to improve strength.  Interdisciplinary or multidisciplinary pain 
management and rehabilitation approaches are recommended for high-intensity chronic 
pain patients at high risk for opioid use disorder to coordinate physical, vocational, and or 
psychological components of care (Chou et al, 2009).   
Prevention, assessment, and treatment of chronic pain is challenging.  Insufficient 
evidence exists that pain relief is sustained or function is improved when opioids are 
prescribed for chronic pain (Paone et al., 2011).  To prevent misuse providers should 
avoid prescribing opioids for chronic pain unless other pharmacological and or non-
pharmacological approaches have been ineffective.  Also, whenever possible, opioids 
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should not be prescribed in patients taking benzodiazepines because of the risk of fatal 
respiratory depression (Paone et al., 2011). Chronic opioid therapy (COT) to treat pain, 
aside from severe acute pain or chronic malignant pain, remains a topic of controversy.   
Selection of patients for an opioid trial should follow weighing of potential benefits and 
risks of COT (Paone et al., 2011).   
Management of Pain by Healthcare Professionals  
Pain is one of the most common reasons for health care visits; however, most 
health professionals’ educational programs do not adequately prepare them to effectively 
manage pain.  Core competencies such as basic knowledge, assessment, team-based care 
and cultural competency are integral.  The National Pain Strategy recommends 
strengthening evidence base for pain prevention strategies, assessment tools, and outcome 
measures.  Rigorously researched efforts are warranted.  This is particularly relevant to 
primary care.  Improvements in self-management strategies in patients with chronic pain 
are also necessary.  Treatment should start with a comprehensive approach.  Plan of care 
should address biological, psychological and social aspects (The Interagency Pain 
Research Coordinating Committee, 2015).   
Researchers note no single practice change in prescribing behavior alleviates all 
risks.  Still, regular monitoring and reassessment provide opportunities to minimize the 
risks associated with long-term opioid use by allowing for the tapering and discontinuing 
of opioids among patients who are not receiving a clear benefit or among those who are 
engaging in practice that increase the risk of overdose (Volkow & McLellan, 2016).  
Examples of such practice are consumption of high doses of alcohol, concurrent use of 
benzodiazepines, and poor adherence to opioid medication regimen.  Prevention of drug 
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diversion, reduction of risk of overdose, and minimization of the risk of addiction are 
presented as goals.  Recommendations to achieve this involves increased use of evidence-
based prescribing and management practices.  The extended prescription of opioids for 
the treatment of chronic pain has questionable benefits, and the risks of overdose 
increases with higher doses.  There is also a call for increased research on pain.  
Discovery-oriented research has been recommended to identify potent non-opioid 
analgesics and other pain treatment strategies (Volkow & McLellan, 2016).   
Screening for Opioid Misuse/Abuse Risk   
Clinicians need to identify patients at risk of misusing prescribed opioids in order 
to safely monitor therapy.  Opioid misuse carries the risk of development of addiction, 
overdose, and death (Claxton & Arnold, 2011).  Providers must balance each patient’s 
pain and risk levels.  Patients with higher risk should be monitored more intensely than 
patients with lower risk.  Risk factors for misuse may be grouped into three categories (1) 
biological, (2) social, and (3) psychological.  Biological risk factors are family history of 
drug abuse and male gender.  Poor social support and history of drug-related criminal 
chargers are social risk factors.  Finally, psychological risk factors include personal 
history of substance abuse, preadolescent history of sexual abuse, and comorbid 
psychiatric illness.  Personal history of substance abuse includes alcohol or tobacco.  
Examples of comorbid psychiatric illnesses are major depression, bipolar disorder, and 
personality disorder (Claxton & Arnold, 2011). 
Screening Tools for Opioid Misuse/abuse 
Common screening tools for opioid misuse in patients with chronic pain are 
Screener and Opioid Assessment for Pain Patients (SOAPP) and the Opioid Risk Tool 
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(ORT).  However, these tools have not been fully validated.  The SOAPP predicts risk for 
possible aberrant drug behavior using a 14 item self-report.  Responses are based on a 5-
point Likert scale.  With 7 as a cutoff score, the test has sensitivity of 91%, specificity of 
69%, positive predictive value (PPV) of 71%, negative predictive value (NPV) of 90% 
(Claxton & Arnold, 2011).  The ORT is a 5 item yes or no tool which predicts the 
probability of opioid misuse or abuse among patients being considered for opioid therapy 
for chronic pain.  Patients are categorized as low, medium, and high risk.  Sensitivity and 
specificity for patients who score at least medium risk are 99% and 16% respectively.  
The tool is best applied in primary care settings.  Clinicians must be aware these 
screening tools have been used in studies to identify high-risk patients.  The tools are not 
diagnostic of substance use disorders or to accurately identify patients who should not be 
prescribed opioids for chronic pain (NIDA, 2015).  Furthermore, they do not assess the 
risk of diversion of drugs.  Regardless of if a provider chooses to use a tool, a thorough 
history is crucial to identify patients who require closer assessment, monitoring and or 
referral (Claxton & Arnold, 2011).    
Evidence supporting risk assessment tools for identification and prevention of 
opioid use disorder is inconsistent.  Standardized tools lack sufficient sensitivity and 
specificity (Shapiro et al., 2013).  Still, screening is paramount assuming all patients are 
at risk.  Fundamental comprehensive clinical assessment is necessary for all patients 
taking opioids for management of chronic pain.  Evaluation should include (1) pain 
intensity appraisal; (2) functional status; (3) quality of life and (4) known risk factors for 
potential harm.  Known risk factors are (a) medical comorbidity, (b) history of substance 
use disorders or current substance use, (c) mood disorders and (d) concurrent use of 
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medications with potential drug-drug interactions.  Patients at highest risk for harm 
should have more structured monitoring during follow-up visits at regular intervals 
(Reuben et al., 2015).  A comprehensive assessment, evaluation of risk, screening, brief 
intervention and referral to treatment are indicated in the clinical setting when managing 
patients presenting with complaint of chronic pain.   
Screening, Brief Intervention, and Referral to Treatment (SBIRT) 
The SBIRT model was developed following an Institute of Medicine 
recommendation which solicited community-based screening for health risk behaviors.  
SBIRT consists of three major components.  The first component is screening. 
Screening  
A healthcare professional assesses a patient for risky substance use behaviors 
using standardized screening tools.  Screening provides a quick method of identifying 
patients who use substances at at-risk levels in addition to those who may already 
experience substance use-related issues.  A brief one to three question prescreen is 
administered.  If an individual screen is positive, a longer screening is given.  Screening 
can occur in any healthcare setting (Substance Abuse and Mental Health Services 
Administration [SAMHSA], 2016).   
Suggested screening tools are the drug abuse screening test (DAST), a sensitive 
screening tool for drug abuse.  The ORT has been validated and fits recommendations for 
a longer screening tool.  Utilizing the SBIRT model in a study of more than 499, 000 
patients using the DAST, 22.7% of patients were identified as high-risk users or had a 
current substance use disorder.  There was a 67.7% decline in reported illicit drug use at 
follow-up (McCance-Katz & Satterfield, 2012).  Those who received specialty 
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experienced great improvements in general and mental health; employment; housing 
status; and criminal behavior.   
Opportunities for early intervention involving at-risk substance users include 
primary care centers, emergency rooms, trauma centers, and other community health 
settings.  Screening assesses severity of and identifies the appropriate level of treatment.  
The Center for Substance Abuse Treatment/Substance Abuse and Mental Health Services 
Administration has launched a training program to foster SBIRT clinical skills in support 
of innovations and implementation of SBIRT.  In addition, reimbursement billing codes 
exist for providers that implement SBIRT.  Current procedural terminology or CPT codes 
used are: CPT 99408 for alcohol and or substance abuse structured screening from 15-30 
minutes and CPT 99409 for alcohol and substance abuse structured screening exceeding 
30 minutes commercial insurance billing purposes; G0396 and G0397 codes may be used 
for Medicare for alcohol and/or substance use (not tobacco) structured assessment and 
brief intervention 15-30 minutes and greater than 30 minutes, respectively; and  H0049 
and H0050 may be used to bill for Medicaid alcohol and/or drug screening (McCance-
Katz, & Satterfield, 2012; SAMHSA, 2016). 
Brief Interventions 
Brief interventions are evidence-based practice designs aiming to motivate 
individuals at risk of substance abuse to make behavior changes.  A healthcare 
professional engages a patient in a short conversation, providing feedback and advice.  
Brief intervention can also be used for at-risk patients to become more receptive to utilize 
referral services.  In primary care settings, brief interventions consist of 5 minutes of brief 
advice.  The interventions are ideal to treat problematic or risky substance use—not 
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intended to treat individuals with serious substance dependence.  Cognitive behavioral 
therapy and motivational interviewing, or a combination of the two, are the two most 
common behavioral therapies used in SBIRT programs (SAMSHA, 2016).  Brief 
intervention without cognitive behavioral therapy will be used for this project.   
FLO and BNI are acronyms for two common forms of motivational interviewing.  
Each will be discussed in this section.  Brief Negotiated Interview and Active Referral to 
Treatment (BNI-ART):  Provider Training Algorithm (Appendix A) is a flowchart 
created by the Boston University School of Public Health which includes brief screening 
questions health practitioners can ask during brief intervention. Steps includes a listing of 
questions and responses that a health provider can use during a brief intervention.  With 
BNI, providers raise the subject, provide feedback, enhance motivation, and negotiate 
and advise. The tool focuses on; building rapport initially; then raising the subject and 
discussing daily life; discussing pros and cons of use; asking permission; giving 
information, and eliciting reaction; discussing readiness to change, and reinforcing 
positives; creating an action plan; and identifying strengths.  The final stage is 
prescription for change which involves writing down an action plan and sealing the deal.    
Patients are provided handouts and follow-up to discuss progress is suggested 
(SAMSHA, 2016).   
The FLO Model includes providing F-feedback, L-listening and understanding, 
and exploring O-options.  FLO is often reinforced with S.E.W.  S-summarize patient’s 
statements in favor of change.  E-emphasize their strengths.  W-what agreement was 
reached?  (SAMSHA, 2016).  
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Referral for Treatment   
Referral is provided for patients who screen high risk and need additional 
services.  Referral to treatment is critical yet often underutilized (SAMSHA, 2016).  The 
process consists of assisting with accessing specialized treatment.  Community Care of 
North Carolina (CCNC) has developed a set of three referral forms in partnership with 
other stakeholders to orchestrate easier consultation and follow-up.  These are Bridging 
the Gap Between Primary Care and Behavioral Health-Referral Forms (SAMSHA, 2016).  
An in-house referral form will be used for this project.     
 In summary, the review of literature shows that implementing SBIRT (SAMSHA, 
2016) and other evidence-based practice recommendations (CDC, 2016) are effective in 
minimizing the risk for misuse of opioid pain medication.  Opioid therapy for chronic 
pain is associated with increased risk of misuse and overdose as well as other physical 
conditions (CDC, 2016). Experts suggest inappropriate prescribing contributes to misuse 
of prescription opioid pain medication (Shapiro et al., 2013). The American Pain Society 
(APS) (2016) states a reliable instrument for identifying aberrant drug-related behaviors 
could be valuable for ongoing monitoring of risks and benefits of chronic opioid therapy.  
ORT should be used with other combined strategies.  The APS and American Academy 
of Pain Medicine (AAPM) (2016) recommend coordination of care when the services of 
other health care professionals are needed.  Coordination of care also minimizes misuse 
of opioid pain medications.  Prescribers should make referrals as needed. The American 
Society of Addiction Medicine (ASAM, 2016) recommends a combination of 
psychosocial interventions and medications for the treatment of opioid use disorder.  A 
table summarizing the ROL can be found in Appendix B.   
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Using the Iowa Model of evidence-based practice (Titler et al., 2001), this DNP 
project will ask the question; find the evidence; appraise; act; evaluate and reflect to 
ensure mitigation of risks related to opioid misuse (Schaffer, Sandau, & Diedrick, 2013).  
This DNP project will ask the question are providers utilizing evidence-based guidelines 
which include implementation of SBIRT prior to prescribing opioid pain medication.  
Finding and appraising of the evidence was carried out through relevant review of 
literature.  Acting will require education of the providers on prescription opioid drug 
misuse and the importance of utilizing evidence-based guidelines in practice.  In addition, 
SBIRT will be implemented over a 4-6-week period with all initial encounters involving 
patients requesting a prescription for an opioid pain medication.  Evaluation and 
reflection is necessary to ensure mitigation of risks related to opioid misuse (Schaffer et 
al., 2013).  Specifically, the project will evaluate whether implementing SBIRT in 
conjunction with evidence-based guidelines by nurse practitioner providers mitigates the 
risk for prescription opioid pain medication misuse and abuse among patients requesting 
a prescription for opioids in a primary care setting. 
Conceptual Framework  
 The conceptual framework used for this project is the SBIRT Program Matrix.  
This framework is used for program implementation and evaluation.  SBIRT Program 
Matrix has five components: (1) SBIRT services; (2) performance sites; (3) provider 
attributes; (4) patient/client populations; and management structure and activities.  
Implementation outcomes include but are not limited to program adoption, fidelity, costs, 
and grant compliance (Del Boca, McRee, Vendetti, & Damon, 2017).  SBIRT services 
includes risk factors, instruments, approaches, procedures.  Examples are pre-screening, 
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screening, brief intervention, referral to treatment, brief treatment, and added services.  
Participating providers will offer SBIRT services using the five components of this model 
at a rural health primary care clinical site.  Screening with the ORT for those with a 
positive preliminary screen will be carried out.  Brief intervention and referral to 
treatment will be implemented for high-risk patients.  The performance site is a federally 
qualified health center and patient-centered medical home.  The NP provider attributes 
include management of patient population through knowledge and structured skills 
obtained from appropriate educational tools and resources.  Additional provider attributes 
include personal characteristics, clinical training, educational attainment, self-efficacy, 
treatment philosophy, and counseling experience.  For this project, patient/client 
population presenting requesting an opioid prescription will be assessed for risk status, 
demographic characteristics, and physical and mental health.  Management structures and 
activities include evidence-based protocols; coaching and staff evaluation; program 
evaluation and dissemination; as well as facilitative administrative supports, systems 
interventions and sustainability planning are all necessary components of SBIRT program 
implementation and evaluation (Del Boca et al., 2017).   
DNP Essentials 
 The project aims to implement a change in prescribing practices of NP primary 
care providers at a primary care health center in efforts to mitigate the risk of misuse of 
prescription opioid pain medications in patients requesting a prescription for opioid pain 
medication.   DNP essentials and competencies (American Associations of Colleges of 
Nursing, 2014) are fulfilled upon completion of this DNP project (Appendix C).  
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Evaluation Plan 
The logic model (Appendix D) demonstrates how the project director will 
evaluate outcomes. The project director used the SBIRT tool to provide training to 
stakeholders.  Stakeholders in this study are identified as nurse practitioner providers who 
treat patients that present requesting prescriptions for opioids with the potential for opioid 
misuse if opioid pain medication is prescribed.  The project director (PD) trained the 
providers and administrators on the risk as well as appropriate use of the SBIRT 
algorithm with incorporation of ORT.  The providers then implemented the use of the 
tool in the clinical setting.  The PD will evaluate adherence to the training and fidelity to 
use of the instrument by analyzing administration of the tool in the clinical setting, use of 
intervention after assessing risk, and whether an opioid was prescribed. The analysis will 
reach the medium-term goals with the idea that the accurate implementation of the tool 
and following risk assessment protocols could potentially lead to a reduction in opioid 
misuse and abuse. 
Assumptions 
The assumption is once educated providers change their prescribing habit and 
adopt evidence-based practice recommendations, the risk of patients misusing 
prescription opioid pain medications will be lowered.  Patients will have improved 
overall health outcomes, and costs will be lowered for insurers and consumers alike.     
Purpose of the DNP Project 
The purpose of the DNP project is to determine if nurse practitioner providers are 
implementing evidence-based practice guidelines including Screening, Brief Intervention, 
and Referral to Treatment (SBIRT) (McCance-Katz & Satterfield, 2012) to mitigate risk 
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of prescription opioid pain medication misuse and abuse among patients who request a 
prescription for opioid pain medication.  
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CHAPTER II - METHODS 
The purpose of this DNP project was to determine if nurse practitioners (NPs) in a 
primary care setting were utilizing screening, brief intervention, and referral for treatment 
(SBIRT), prior to prescribing opioid pain medications for patients seen on an initial visit 
requesting a prescription for opioid pain medication. The desired outcome was to 
mitigate the risk for opioid pain medication misuse or abuse while providing appropriate 
chronic pain management.   
Setting 
 The setting was a patient-centered medical home (PCMH), designated as a 
federally qualified health center (FQHC) located in rural Mississippi.  The clinic serves 
pediatric to geriatric patients. Most of the patient population receives Medicare and/or 
Medicaid benefits; a sliding scale fee is offered to eligible patients who are uninsured, 
and private insurance is also accepted at the facility.  Services offered include internal 
medicine; pediatrics; women’s health; women, infants and children (WIC); dental; vision; 
pharmacy; and social services.   
 There are four clinic locations:  Site 1 (main clinic), Site 2, Site 3, and Site 4 
(satellite clinics).  There are five NPs on staff at the main clinic—3 full-time, 1 part-time, 
and 1 that works as needed (prn).  Both Sites 2 and 3 are staffed by 1 full-time NP each 
but were excluded from the project.  Site 4 is only staffed by medical doctors and was 
excluded from the project.  The DNP project was only conducted with the five full-time 
nurse practitioners that see patients age 18 to 45 years of age at the main clinic-Site 1.   
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Population 
 Participants included nationally certified adult-gerontological and family nurse 
practitioners, AGNPs (N=2) and FNPs (N=3). The full-time NPs are licensed to practice 
in the state of Mississippi and work at the primary care main clinic setting.  All five of 
the participants completed 720 hours of monitored practice as required by the Mississippi 
Board of Nursing (MSBN, 2016) deeming them eligible for controlled substance 
prescriptive authority (CSPA).  The majority of patients between the ages of 18-45 years 
of age with a diagnosis of chronic pain are seen by nurse practitioners; therefore, nurse 
practitioner prescribers were the targeted populations for the DNP project.   
Design 
 The design was descriptive in nature.  The protocol describes the implementation 
of SBIRT in patients requesting a prescription for an opioid pain medication seen by NPs 
in a primary care setting.  The primary project outcome was identification of risk for 
opioid misuse or abuse in patients, while secondary or long-term outcomes include 
reduction in misuse of opioids, better prescribing practices, healthcare cost reductions, 
and improvement in public health and safety.     
Procedures 
Education Session   
The project director is a full-time FNP employee, with CSPA, at a primary care 
clinic in southeastern Mississippi.  In a one-on-one educational session, NP providers 
were educated by the project director on current evidence-based opioid guidelines to 
include conducting a comprehensive assessment and screening for opioid misuse/abuse, 
brief intervention, and referral for treatment (SBIRT) (CDC, 2016; SAMHSA, 2016).   
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 The educational session covered the most common pain diagnoses seen in the 
clinic; conducting a comprehensive assessment, and implementation of SBIRT. The 
project director defined chronic pain and all applicable ICD-10 diagnosis codes, 
excluding active cancer; palliative; or end-of-life-care. Participants were educated on 
how to conduct a comprehensive assessment based on evidence-based guidelines (CDC, 
2016) and implement Screening, Brief Intervention, and Referral for Treatment (SBIRT) 
(SAMSHA, 2016).  NP participants were also instructed to use the prescription 
monitoring program (PMP). Education was provided on known risk factors such as 
illegal drug use; prescription drug use for nonmedical reasons; history of substance use 
disorder or overdose; and mental health conditions.  
 Screening in SBIRT was modified to use a screening tool that identifies risk for 
opioid use or misuse rather than the longer screening for substance use-DAST. The 
participants were also educated regarding use of the Opioid Risk Tool (ORT) developed 
by Lynn R. Webster, MD (Appendix E).  The tool is a self-report screening tool to assess 
risk for opioid abuse or misuse in individuals, age 16 to 45 (National Institute on Drug 
Abuse [NIDA], 2015).   The ORT addresses family as well as personal history of 
substance abuse—alcohol, illegal and prescription drugs.  History of preadolescent sexual 
abuse and questions regarding psychological disease are included.   Providers were 
advised to read the tool to the patient when administering the tool and assigning points 
based on patient’s responses.  Points were assigned based on male or female sex. Points 
were then summed up by providers to note mild, moderate, or high risk.  The ORT has 
been validated in both males and females with a diagnosis of chronic pain.  In a 
preliminary study, a high degree of sensitivity and specificity was shown using a c 
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statistic for validation.  Excellent discrimination was displayed, c=0.82 male and c=0.85 
female.  Patients categorized as high-risk are at increased likelihood of developing opioid 
use disorder (OUD) (NIDA, 2015).    
Providers were informed on brief interventions to implement and referral for 
treatment based on scoring of the ORT. Brief interventions should be utilized for patients 
identified as mild to moderate risk prior to prescribing opioid pain medication.  Providers 
were instructed on using a brief negotiated interview (BNI), motivational interviewing for 
a period of 5 minutes (SAMSHA, 2016).  Patients identified as high risk were referred for 
behavioral health/addiction services in addition to brief intervention.  A list of referral 
sites in the surrounding area was provided for providers.  
Consent   
After the educational session, providers were asked to participate in the proposed 
project.  Providers were informed of the project and informed consent for participation 
was obtained from all providers willing to participate in the project.  All practitioners 
were made aware of the option to opt out of the project.  For those participants willing to 
participate in the project after being invited and having received the informed consent 
statement, data collection tools were provided.  An overview of completing the data 
collection tools after implementing SBIRT was provided for participating providers.  
SBIRT Implementation 
 Participants were instructed on implementing SBIRT in patients that presented 
for an initial visit requesting a prescription for an opioid pain medication over a 4 to 6-
week interval in a primary care clinic in rural southeastern Mississippi.  Participants 
implemented SBIRT on all new patients meeting criteria, age 18-45 and requesting a 
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prescription for an opioid pain medication.  Based on the review of literature (NIDA, 
2015) which noted young adults age 18-45 at highest risk for misuse, patients less than 18 
years of age or older than 45 years of age were excluded.   Pregnant patients are also 
excluded due to vulnerability  
 Before prescribing opioid pain medications, providers were informed to conduct a 
comprehensive assessment based on evidence-based guidelines (CDC, 2016) on any 
individuals meeting inclusion criteria during an initial visit requesting pharmacological 
treatment with an opioid pain medication.   Prescreen data was collected by participating 
NP providers to identify patients’ risk for OUD.  A comprehensive assessment included a 
risk assessment and interventions, including referral for treatment for opioid use disorder, 
and was provided based on the results or the risk assessment (SAMSHA, 2016) 
(Appendix F).  Patients were first asked about past drug use to determine whether 
additional screening was necessary: In the past year, how many times have you used 
illegal drugs and/or prescription drugs for nonmedical reasons (prescreen)?  If the risk 
screen was negative, participants followed evidence-based guidelines (CDC, 2016) but 
did not report on negative screens.  If the preliminary screening was positive, risk level 
was determined further through the Opioid Risk Tool (ORT) which was provider 
administered. Participants provided brief intervention as needed.  Brief intervention 
consisted of 5 minutes of motivational interviewing to assess readiness for positive 
behavioral change.  All patients received screening and/or brief intervention depending 
on risk level.  Brief intervention was utilized for patients identified as mild, moderate, or 
high risk prior to prescribing opioid pain medication.  This project focused on 
motivational interviewing (BNI) for a period of 5 minutes (SAMSHA, 2016).  Patients 
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identified at mild or moderate risk were treated according to the CDC (2016) guidelines 
for prescribing opioids for chronic pain.  Only patients at high risk received referral for 
treatment.  Patients at high risk were referred to local behavioral health/addiction 
services.  
Data Collection 
 A data collection tool, the ORT, BNI, and list of referral sources was provided to 
participants.  Participants administered and documented results of the ORT and BNI 
during patient visits.  Data was documented on a data collection tool by NP providers.  
Patients were categorized on the data collection tool by age group; sex; level of risk for 
opioid abuse (low: 0-3, moderate: 4-7, or high >8); and brief intervention treatment (yes 
or no) with prescription for opioid treatment (yes or no); or referral for treatment (yes or 
no).     
 Ethical Protection of Human Subjects 
There were minimal risks of harm to participants associated with this project. The 
project consisted primarily of participants, nurse practitioners (NP) providers, 
documenting screening, brief intervention, referral for treatment on a data collection tool. 
Data documented was reported in the aggregate, no single person was identified.   
Data was anonymous via de-identification and was protected using coding, and cannot be 
associated with individual subjects; therefore, loss of privacy and breach of 
confidentiality was not a risk. Although the project director knows who the providers 
\were, the association of providers to which data was accessible, only by listing the first 
initial of the provider's last name.  The project director will made weekly follow-ups to 
answer any questions and ensure fidelity of procedure.  
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The project consisted of data with no identifying information. Data was recorded 
on the ORT and other data collection tools by the trained data collectors so that subjects 
could not be identified, directly, or through identifiers linked to the subjects. To ensure 
confidentiality and anonymity, subjects’ information was stored using codes assigned on 
the data collection form.  Data on the data collection tool was stored under double locks 
in the office files of the data collector at the clinic. The data collector was the only person 
who had access to the double locked office file. The data collection tools were placed in 
an envelope by the data collector to be given to the project director (PD) on a weekly 
basis for analysis and completion of the project. The project director provided any 
assistance necessary to ensure efficiency of data collection. 
Information on the data collection tool was entered in an Excel spreadsheet by the 
project director to maintain confidentiality.  Data was recorded and summarized by the 
Project Director so that subjects could not be identified, directly, or through identifiers 
linked to the subjects.  Electronic data wad stored on a password protected computer.  
Confidentiality was protected by placing all physical data collected in a locked file box 
that was kept in the office of the PD and only the PD had access to the locked file box 
and drawer.  All collected data forms will be destroyed by shredding after completion of 
the project 6 months post-graduation from the DNP degree program. 
Participation in the DNP project was completely voluntary without risks or 
incentives and any participant had the option to decline participation at any time without 
penalty.  Providers who agreed to participate may have feared occupational consequences 
if they did not participate, but were assured of no consequences for nonparticipation on 
the consent given prior to participation.  Other inconveniences that the NP participants 
 34 
may have experienced were time constraints in implementing a component of an 
evidence-based guideline into daily practice.  
Potential benefits participants may have gain as a result of participation in the 
project were improved evidence-based prescribing practice to minimize the risk for 
opioid pain medication misuse/abuse among patients seen by NPs in a primary care 
setting.  In addition to identification of risk for opioid misuse or abuse and reduction in 
misuse of opioids, additional benefits included healthcare cost reductions and 
improvement in public health and safety.   
Data Analysis 
The project director evaluated use of evidence-based practice recommendations 
for SBIRT to include outcome categories of risk assessment screening for opioid 
abuse/misuse; brief intervention and referral.  Data was retrieved through data collection 
tools provided to providers to answer the PICOTs question: “In patients 18-45 years of 
age, who present to a primary care clinic requesting a prescription for opioid pain 
medication, will screening by nurse practitioners identify patients at risk for opioid abuse 
leading to appropriate intervention or referral?” Data was stratified based on age (18-25), 
(26-35), (36-45); sex (male or female), risk level (low, moderate, high), opioid therapy 
initiated (yes or no), brief intervention (yes or no) and referral (yes or no).  Patient 
follow-up information was not included in this project.  Data was analyzed using 
descriptive statistics. 
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CHAPTER III  - RESULTS 
The purpose of this DNP project was to determine if nurse practitioners in a 
primary care setting are implementing evidence-based practice guidelines (CDC, 2016) to 
mitigate risk of prescription opioid pain medication abuse among patients who request a 
prescription for opioid pain medication.  During the 4 week period of data collection, 
beginning February 1st and ending March 1st, 12 patients were identified that met criteria 
for inclusion in the study.  Two NP providers participated in data collection for the study 
and saw 100% of the patients.     
The ORT revealed 42% (5) of patients had a family history of alcohol abuse; 17% 
(2) patients had a family history of illegal drug abuse, and 0.08 % (1) patient had a 
personal history of illegal drug abuse.  25% (3) of patients had a history of preadolescent 
sexual abuse, while17% (2) of patients had a history of attention deficit disorder (ADD), 
obsessive compulsive disorder (OCD), bipolar, and/or schizophrenia and 42% (5) of 
patients had a history of depression.  There were several identified risk factors for which 
none of the patients reported having, such as, family history of prescription drug abuse, 
and personal history of alcohol abuse.  All descriptive data are represented in Table 2. 
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Table 2  
Descriptive Statistics 
 N Minimum Maximum Mean 
Std. 
Deviation 
age 12 1 3 1.50 .905 
sex 12 1 2 1.50 .522 
Risk level 12 1 3 1.50 .798 
intervention 12 1 2 1.83 .389 
referred 12 1 2 1.83 .389 
Opioid prescribed 12 2 2 2.00 .000 
FH alcohol 5 1 3 1.80 1.095 
FH illegal drugs 2 3 3 3.00 .000 
FH Rx drugs 0     
PH alcohol 0     
PH drugs 1 4 4 4.00 . 
PH Rx drugs 0     
age1645 12 1 1 1.00 .000 
PA Sex Abuse 3 0 3 1.00 1.732 
ADD_OCD_ETC 2 2 2 2.00 .000 
depression 5 1 1 1.00 .000 
Score totals 12 1 9 3.58 2.999 
Valid N (listwise) 0     
 
 The largest portion of the sample based on age group was age 18-25 comprising 
75% (9) of the total sample size.  The remainder of the study sample was composed of 
36-45 year old making up 25% (3). No patients in the sample fell into the 26-35 age 
range.   The sample was split evenly between males and females.   66% (8) of patients 
were identified as low risk scoring 0-3--everyone scored at least 1 due to age criteria of 
16-45 for use of the ORT.  The average score for the low-risk category was two).   17% 
(2) of patients were identified as moderate risk scoring between 4 and 7.     Lastly, 17% 
(2) of patients were identified as high risk.  These data are represented in Table 2 below. 
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Table 3  
Risk Level 
 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid low 8 66.0 66.0 66.0 
moderate 2 17.0 17.0 83.0 
high 2 17.0 17.0 100.0 
Total 12 100.0 100.0  
 
 Brief intervention was not performed for any of the low to moderate risk patients.    
Brief intervention and referral for treatment was performed in high-risk patients as 
indicated in Table 3.       
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Table 4  
Risk Level Intervention Cross Tabulation 
 
intervention 
Total yes no 
Risk level low 0 8 8 
moderate 0 2 2 
high 2 0 2 
Total 2 10 12 
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CHAPTER IV – DISCUSSION 
This DNP project was designed to implement a change in prescribing practices of 
nurse practitioner (NP) healthcare providers at a primary care health clinic in efforts to 
mitigate the risk of misuse of prescription opioid pain medications in patients requesting 
a prescription for opioid pain medication.   Misuse of prescribed opioid pain medication 
is a problem pertinent to primary care and may be prevented through proper prescribing 
consistent with evidence-based practice recommendations.  NP practitioner providers 
were educated on conducting a comprehensive assessment that includes screening for risk 
of opioid pain medication abuse/misuse (CMS, 2017a).  Education was also provided on 
known risk factors for opioid misuse and abuse such as illegal drug use; prescription drug 
use for nonmedical reasons; history of substance use disorder or overdose; and mental 
health conditions. Risk level for misuse and abuse of opioid pain medication was 
identified through screening using the Opioid Risk Tool (ORT) for those patients with a 
positive preliminary screen.  Brief intervention and referral to treatment was conducted 
for patients identified as high risk for opioid misuse.   
Screening, Brief Intervention, and Referral for Treatment (SBIRT) 
The SBIRT model was developed to screen for health risk behaviors in 
community-based settings.  Risk factors for opioid misuse may be grouped into three 
categories (a) biological, (b) social, and (c) psychological (Claxton & Arnold, 2011). A 
priority area within the CMS (2017a) person-centered strategies to decrease opioid 
misuse is to expand screening, diagnosis, and treatment of opioid use disorder. Screening 
was conducted to identify risk for opioid misuse/abuse and interventions were provided 
to prevent opioid use disorder. Biological and psychological factors that predict OUD 
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were considered when NP participants administered the Opioid Risk Tool (ORT) to those 
patients with a positive preliminary screen. Opioid use disorder (OUD) has been found in 
patients with comorbid mental disorders and physical conditions; therefore, assessing the 
psychosocial components of the ORT and conducting a comprehensive assessment are 
essential in primary care settings (Katz et al., 2013). 
Another priority in the CMS (2017a) opioid misuse strategy is prescribers are to 
increase the use of evidence-based practices for acute and chronic pain management.  
After screening for opioid misuse/abuse risk, treatment should start with a comprehensive 
approach.  The plan of care should address biological, psychological and social aspects 
(Interagency Pain Research Coordinating Committee, 2015). When pain is accompanied 
by comorbidities, clinicians should integrate or refer for therapies that target psychosocial 
factors. Two (17%) of patients received brief intervention, motivational interviewing, and 
were referred for treatment. Pain management and rehabilitation approaches are 
recommended for patients with chronic pain that are identified as high risk for opioid use 
disorder to coordinate physical, vocational, and or psychological components of care 
(Chou et al., 2009).  
Prescribing Practices 
  Safe prescribing models for chronic pain management have been developed for 
prescribing opioids. (CDC, 2016).  The NP participants exercised healthy prescribing 
habits as evidenced by not prescribing any opioid therapy in the 12 patients that presented 
requesting a prescription for an opioid pain medication.  Prescribing practices are directly 
correlated with patient risk--healthy prescribing habits leading to lower risk and 
unhealthy prescribing habits are associated with higher risk (CDC, 2016).  Data reveals 
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implementation of evidence-based guidelines since most patients were low risk, and no 
opioids were prescribed. Implementation of best practice was desired due to 
recommendations against initiating pharmacological therapy with opioids unless other 
pharmacological and nonpharmacological therapies have been ineffective previously 
(CDC, 2016; Paone et al., 2011). The assumption is once educated providers change their 
prescribing habit and adopt evidence-based practice recommendations, the risk of 
patients misusing prescription opioid pain medications will be lowered.   
Limitations 
Only two NP participants implemented SBIRT in 12 patients during the short 
period for the project. While five NP providers were educated on evidence-based 
guidelines for prescribing opioid pain medication and SBIRT, patients that met the 
inclusion criteria for age 18-45 did not present to one provider requesting a prescription 
for opioid pain medication. The patient population seen by the NP were primarily adults 
over the age of 45. Two providers were on medical leave for most of the data collection 
period.  Another limitation of the project is that patients may not have been completely 
honest in responses to the questions on the ORT due to stigma associated with substance 
misuse and other components of the ORT.  For example, all patients denied a family and 
personal history of prescription drug abuse. 
Implications 
Practice Implications  
While conducting a needs assessment for the DNP project, a retrospective chart 
review was conducted which revealed seven patients with a history of substance-related 
disorders with no documentation of a risk assessment performed.  After providing 
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education to NP participants, risk assessments for opioid abuse was conducted on the 12 
patients seen by the NP participants. Routine screening for anxiety/depression and 
substance use disorders in primary care settings is imperative to mitigate risk for adverse 
health outcomes (CDC, 2016). Although no opioids were prescribed by the NP 
participants, known risks should be discussed will all patients prior to prescribing opioid 
pain medication and patient and provider responsibilities should be outlined. Immediate-
release opioids should be prescribed at the lowest effective when starting 
pharmacological therapy (CDC, 2016). 
The prescription monitoring program (PMP) tracks prescribers who may be 
prescribing opioids inappropriately (CMS, 2017a).  Providers should review the PMP on 
patients when starting opioid pain medications and periodically during treatment.  
Experts suggest inappropriate prescribing contributes to misuse of prescription opioid 
pain medication (Shapiro et al., 2013); therefore, NP participants were also instructed to 
use the PMP for this project (CDC, 2016). The project did not evaluate whether the NPs 
accessed and documented use of PMP in the medical record. Accessing the PMP and 
other evidence-based practice guidelines should be followed when prescribing opioid 
pain medications.  
Implications for Theory 
 The conceptual framework used for this project is the SBIRT Program Matrix. 
Participating NPs offered SBIRT services using the five components of the model at a 
rural health primary care clinical site. The project director outlined program planning, 
decision making, design, data collection and use during SBIRT program implementation.  
Implementation outcomes of the SBIRT Program Matrix include but are not limited to 
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program adoption, fidelity, costs, and grant compliance (Del Boca et al., 2017).  
Recommendations for adoption of the SBIRT program at the practice site will need to 
consider not only quality of care but costs and time in implementing SBIRT.  Medicare, 
Medicaid, and commercial insurance reimbursement billing codes exist for providers who 
implement SBIRT (McCance-Katz & Satterfield, 2012; SAMHSA, 2016). With adoption 
and implementation of SBIRT, documentation is also essential and SBIRT forms should 
be scanned into the electronic medical record (EMR). 
The fifth component of the SBIRT model, management structures and activities, 
includes evidence-based protocols; coaching and staff evaluation; program evaluation 
and dissemination; as well as facilitative administrative supports, systems interventions, 
and sustainability planning as necessary components of SBIRT program implementation 
and evaluation (Del Boca et al., 2017). Further evaluation of management structures and 
activities is warranted. Initial evaluation of implementing the SBIRT model for this 
project will be disseminated to stakeholders at the practice site where the project was 
conducted and will be disseminated to interested audiences.   
Policy Implications 
Further efforts should address each component of the SBIRT matrix, especially in 
the areas of coordination of care versus integration of care.  Although SBIRT program 
implementation is effective, patients currently receive care from multiple providers at 
multiple practices sites making the process less seamless than desired.   Nurse 
practitioners can influence practice and policy to mitigate risk for abuse and misuse of 
opioid pain medications.  Utilizing an integrated care approach, dually certified NPs who 
are family nurse practitioners (FNPs), as well as psychiatric mental health nurse 
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practitioners (PMHNPs), are prepared to provide care to individuals with a pain 
diagnoses and OUD with little to no fragmentation of care. Providers should offer or 
arrange evidence-based treatment for patients with opioid use disorder (CDC, 2016).  
Coordinated, co-located, and integrated care are three cores of 
collaboration/integration encompassing six levels.  Coordinated care is based on 
communication involving minimal collaboration (Level 1) and basic collaboration at a 
distance (Level 2) across separate facilities.  Co-location focuses on physical proximity, 
basic collaboration onsite (Level 3) and close collaboration onsite with some system 
integration (Level 4).  Integrated care requires a practice change aiming for close 
collaboration approaching an integrated practice (Level 5) and full collaboration in 
transformed/merged integrated practice (Level 6) (Heath, Wise, & Reynolds, 2013).  
Screening and assessment vary at each level.  Screening and assessment done per 
separate practice models with separate treatment plans results in patients’ physical and 
behavioral health needs being treated as separate issues.  Although patients may be 
referred, a variety of barriers prevent many patients from accessing care.  Close 
proximity allows referrals to be more successful and easier for patients.  There is better 
follow-up when patients are internally referred.  Moreover, the integrated care team 
approach feels like a one-stop shop.  Patients experience a seamless response to all 
healthcare needs in a unified practice (Heath et al., 2013).  Community mental health 
centers (CMHCs) and Federally Qualified Health Centers (FQHCs) are collaborating to 
provide integrated primary and behavioral health services, including addiction services 
(National Council for Behavioral Health, 2016).  In the clinical setting where this DNP 
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project was conducted, close collaboration onsite with system integration will meet the 
needs of individuals with a pain diagnoses and opioid use disorder.  
 Medication-assisted treatment (MAT) is recommended for individuals diagnosed 
with OUD.  MAT, including opioid treatment programs (OPT), combines behavioral 
therapy and medications in the treatment of substance use disorders.    Recent federal 
legislation, the Comprehensive Addiction and Recovery Act (CARA), provisions include 
increasing access to preventive services, medication-assisted treatment (MAT), and 
recovery services. Nurse practitioners with the appropriate education and certification can 
now be trained to treat OUD. NPs are granted privileges to prescribe buprenorphine in 
community-based setting after completing training and receiving a waiver to prescribe 
buprenorphine (SAMHSA, 2017). Since there are limited resources to refer patients for 
treatment if identified as high risk for opioid abuse, developing an integrated care model 
would be beneficial in providing care in one setting. NPs at the setting should keep 
abreast of changes in federal and state laws regarding opioid use disorder prevention and 
treatment so that qualified nurse practitioners are prepared to meet the need for 
preventive services, MAT, and recovery services.  
Recommendations for Future Evaluation 
Screening tools for the assessment of potential risks of opioid therapy are helpful 
for risk stratification.  However, more screening studies are needed to explore outcomes 
and should be expanded across the lifespan, adolescent to elderly.  Tools with construct 
partial validity include the Screener and Opioid Assessment for Patients with Pain 
(SOAPP); the Opioid Risk Tool (ORT); and the Diagnosis, Intractability, Risk, and 
Efficacy (DIRE) instrument.  Regardless of the tool used by a provider, a thorough 
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history is crucial to identify patients who require closer assessment, monitoring and or 
referral (Claxton & Arnold, 2011).  The strongest factor predictive of misuse after 
initiation of opioid therapy is a personal or family history of alcohol or drug abuse.   
Further evaluation is warranted specifically on the correlation of prescribing practices 
and risk level identified via validated screening tools since researchers have revealed 
patients may misuse after only being prescribed one prescription for opioid pain 
medication (Levi, Segal, & Miller, 2013).    
In addition, evaluation of risk for OUD in vulnerable and special populations such 
as pregnant women are lacking.  Most providers report being inadequately trained to 
effectively treat pain and screen patients for prevention of misuse and abuse (The 
Interagency Pain Research Coordinating Committee, 2015); therefore, outcome studies 
that evaluate knowledge and implementation of evidence-based practices for prescribing 
opioid pain medication should be conducted. Finally, further studies should be performed 
to identify barriers to SBIRT implementation.  Implementation outcomes of the SBIRT 
framework are adoption; acceptability; appropriateness; feasibility; fidelity; 
implementation costs; penetration; sustainability; service provision to at-risk populations; 
and (if applicable) grant compliance (Del Boca et al., 2017).  All components of the 
SBIRT framework require further evaluation. NP participants for the DNP project voiced 
concern regarding time constraints and costs. However, as mentioned previously, SBIRT 
interventions are billable for commercial insurance, Medicare, and Medicaid.  Again, 
evaluation should be conducted to assess the cost of adopting, implementing, and 
sustaining SBIRT and other evidence-based practice recommendations.   
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Conclusions 
Due to the epidemic stemming from misuse of opioid pain medications, the CDC 
(2016) has implemented evidence-based guidelines to aid in risk mitigation. 
Implementation of evidence-based guidelines promotes proper prescribing practices 
which are directly correlated with patient risks (Katz et al., 2013). This DNP project was 
carried out to evaluate if nurse practitioner providers are utilizing appropriate screening 
to identify risk for opioid misuse in patients requesting opioid pain medications.  Low-
risk levels for opioid pain medication misuse was identified among mostly young adults. 
Young adults are an ideal population to implement interventions to mitigate risk 
(SAMHSA, 2016).   Project outcomes extend beyond improved patient outcomes but also 
promote better-prescribing practices by NP providers.  Implementing SBIRT in the 
clinical setting conjunctly with other validated screening tools could prove to be quite 
effective in combating misuse of opioid pain medication. 
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APPENDIX A – Brief Negotiated Interview Algorithm 
BRIEF NEGOTIATED INTERVIEW (BNI) ALGORITHM  
 
1) BUILD RAPPORT Tell me about a typical day in your life.  
 Where does your current [X] use fit in?  
Help me understand, through your eyes, the good things about 
using [X].    What are some of the not‐so‐good things about 
using [X]?    So, on the one hand [PROS], and on the other hand 
[CONS].  
 
2) PROS & CONS Summarize I have some information on low‐
risk guidelines for drug use, would you mind if I shared them 
with you? We know that use of illicit drugs such as        ___ 
…can put you at risk for social or legal problems, as well as 
illness and injury.  It can also cause health problems like [insert 
medical information].    What are your thoughts on that?  
 
3) INFORMATION & FEEDBACK Elicit Provide Elicit This 
Readiness Ruler is like the Pain Scale we use in the 
hospital.    On a scale from 1‐10, with 1 being not ready at all 
and 10 being completely ready, how ready are you to change 
your [X] use?       You marked ___.  That’s great.  That means 
you are ___ % ready to make a change. Why did you choose that 
number and not a lower one like a 1 or a 2?   
 
4) READINESS RULER Reinforce positives Ask about lower #  
 
5) ACTION PLAN Identify strengths & supports Write down 
steps Offer appropriate resources.  What are some steps/options 
that will work for you to stay healthy and safe?  What will help 
you to reduce the things you don’t like about using [X]?    What 
supports do you have for making this change?     Tell me about a 
challenge you overcame in the past.  How can you use those 
supports/resources to help you now?    Those are great ideas! Is it 
okay for me to write down your plan, your own prescription for 
change, to keep with you as a reminder? Will you summarize the 
steps you’ll take to change your [X] use?     
I have some additional resources that people sometimes find 
helpful; would you like to hear about them?   • Primary Care, 
Outpatient counseling, Mental Health • Suboxone, Methadone 
clinic, Needle Exchange, AA/NA, Smoking cessation • Shelter, 
Insurance, Community Programs • Handouts and information     
Thank patient Thank you for talking with me today.  
BNI-ART Institute, www.bu.edu/bniart 
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APPENDIX B –Review of Literature Table 
 
Authors/ 
Year 
Design/ 
Sample/ 
Setting 
Framework/ 
Intervention/ 
Measures 
Goal/ 
Aim 
Outcomes/ 
Findings 
 
American 
Academy 
of Pain 
Medicine 
  Screening tools 
to aid in 
prevention 
Reliable 
instrument for 
identifying 
aberrant drug-
related 
behaviors 
could be 
valuable for 
ongoing 
monitoring of 
risks and 
benefits of 
chronic opioid 
therapy     
 
American 
Pain 
Society 
  Treatment 
approach to 
prevent and treat 
misuse/abuse  
Recommends 
coordination of 
care when the 
services of 
other health 
care 
professionals 
are needed 
American 
Society of 
Addiction 
Medicine 
(ASAM) 
(2016) 
Guideline  Coordination/int
egration of care 
Recommends a 
combination of 
psychosocial 
interventions 
and 
medications 
for the 
treatment of 
opioid use 
disorder.   
Centers for 
Disease 
Control and 
Prevention 
Systematic 
review 
Analysis of 
articles 
Promote better 
opioid 
prescribing 
practices 
12 
recommendatio
ns for 
management of 
chronic pain 
 50 
(CDC) 
(2016) 
with opioid 
pain 
medication 
Chou et al 
(2009) 
Report of 
evidence by 
expert panel 
14 
systematic 
reviews; 57 
primary 
studies 
8,034 abstracts Pathway to 
prevention of 
opioid 
misuse/abuse 
Consideration 
of the 
effectiveness 
of non-opioid 
therapy should 
precede 
chronic opioid 
therapy (COT).  
Screening tools 
for the 
assessment of 
potential risks 
of COT are 
helpful for risk 
stratification. 
Claxton & 
Arnold 
(2011) 
 Analysis of 
articles 
 Common 
screening tools 
for opioid 
misuse in 
patients with 
chronic pain 
are Screener 
and Opioid 
Assessment for 
Pain Patients 
(SOAPP) and 
the Opioid 
Risk Tool 
(ORT).   
McCance-
Katz & 
Satterfield 
(2012) 
 499,000 
patients 
Integrate 
prevention and 
treatment of 
substance abuse 
A key to using 
SBIRT in 
primary care 
settings 
Utilizing the 
SBIRT model, 
there was a 
67.7% decline 
in reported 
illicit drug use 
at follow-up.   
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National 
Institute on 
Drug 
Abuse 
(2015) 
  To prevent 
opioid use 
disorder (OUD) 
Overview of 
opioid risk tool 
(ORT) and its 
validation in 
screening for 
opioid 
misuse/abuse  
Paone, 
Dowell, 
Heller 
(2011) 
Report 
City health 
information 
 Preventing 
misuse of 
prescription 
opioid drugs 
To prevent 
misuse 
providers 
should avoid 
prescribing 
opioids for 
chronic pain 
unless other 
pharmacologic
al and or non-
pharmacologic
al approaches 
have been 
ineffective.  
Selection of 
patients for an 
opioid trial 
should follow 
weighing of 
potential risks 
and benefits of 
COT. 
Reuben et 
al 
(2015) 
National 
Institute of 
Health 
  Patients at 
highest risk 
should have 
more 
structured 
monitoring 
during follow-
up visits at 
regular 
intervals. 
Shapiro, 
Coffa, 
McCance-
Katz 
(2013) 
 An effective 
office-based 
approach 
includes a 
coherent 
framework for 
 Use of 
motivational 
rather than 
confrontational 
communication 
is best during 
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identification of 
risk to promote 
behavioral 
change 
screening, 
counseling, 
and treatment 
to improve 
patient 
outcomes.   
Substance 
Abuse and 
Mental 
Health 
Services 
Administrat
ion 
(SAMHSA
) (2016 
 Comprehensive, 
integrated, 
public health 
approach 
 The SBIRT 
initiative is a 
comprehensive 
approach used 
in substance 
abuse.   
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APPENDIX C –DNP Essentials 
DNP Essentials DNP Essentials and Competencies Met 
DNP Essential I 
Scientific underpinning for practice 
Development, implementation, and 
evaluation of new practice approaches 
based on evidence-based clinical practice 
guidelines (EBCP) and the SBIRT 
conceptual framework was conducted for 
the DNP project. The pilot integration of 
the SBIRT program matrix framework 
provides an understanding of the 
conceptual model for program 
implementation and evaluation.   
DNP Essential II 
Organization and systems leadership 
for quality improvement and systems 
thinking 
Development and evaluation of a new 
care approach met the current and future 
needs of the organization, providers, and 
patients. Accountability for quality health 
care for the organization and patient 
safety were met by educating nurse 
practitioners regarding current EBCP 
guidelines and validated tools to identify 
and mitigate risk for opioid misuse and 
abuse among patients.   
DNP Essential III 
Clinical leadership and analytical 
methods or evidence-based practice 
Leadership skills were exemplified by the 
project director functioning as a practice 
specialist/consultant in a collaborative 
evidence-guided practice. Information 
technology and research methods were 
used in the design and evaluation of the 
project.  Critical appraisal of the existing 
scientific literature was conducted to 
implement the best evidence for practice. 
Translation of research into the practice 
setting was implemented to improve 
healthcare outcomes.   
DNP Essential IV 
Information systems or technology 
and patient care technology for the 
improvement and transformation of 
healthcare  
Utilization of information systems was 
conducted during the need’s assessment to 
evaluate outcomes of care and quality 
improvement. Program design, selection, 
use and an evaluation plan was developed 
and executed to monitor outcomes of care, 
including data abstraction.  Information 
systems/technology improvements in the 
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practice environment were recommended 
upon evaluation of the DNP project.  
DNP Essential V 
Health care policy for advocacy in 
health care 
Patient advocacy and leadership skills 
were used in developing and 
implementing health policies when 
prescribing opioid pain medications.  A 
critical analysis of health policy and 
related issues on prescription opioid pain 
medication misuse/abuse at local, state, 
and federal levels was conducted in 
development and evaluation of the DNP 
project.  
DNP Essential VI 
Inter-professional collaboration for 
improving patient and population 
health outcomes 
Effective communication and 
collaborative skills were utilized in the 
development and implementation of the 
DNP project. The project director led 
interprofessional (medical director, 
administrators, staff) and intraprofessional 
(nurse practitioner) teams to create a 
change in healthcare delivery. 
Improvement of population health 
outcomes was met through risk 
identification in efforts to prevent and 
reduce the risk for opioid misuse/abuse 
among patients presenting to the primary 
care clinic requesting a prescription for an 
opioid pain medication. 
DNP Essential VII 
 
Clinical prevention and population 
health for improving the nation’s 
health 
Aggregate scientific data was analyzed 
related to prescription opioid pain 
medication misuse/abuse. Health 
promotion/disease prevention efforts 
focused on improvement of health status 
and gaps in care for individuals at risk for 
opioid misuse/abuse. The DNNP project 
implemented guidelines and SBIRT to 
prevent misuse and abuse of opioid pain 
medications.   
DNP Essential VIII 
Advanced nursing practice 
Conceptual and analytical skills were 
utilized to evaluate the links among 
practice, organization, population, fiscal, 
and policy issues.  Advanced levels of 
clinical judgment, systems thinking, and 
accountability were achieved in the 
design, implementation, and evaluation of 
evidence-based care to improve patient 
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outcomes. The project director guided, 
mentored, and supported other nurse 
practitioners to achieve excellence in 
nursing practice. A comprehensive and 
systematic assessment of health and 
illness parameters related to opioid 
misuse/abuse in the practice setting was 
conducted for the DNP project.  
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APPENDIX D –Logic Model 
 
 
 
INPUTS 
 
 
OUTPUTS 
 
OUTCOMES 
 
Principal 
investigator 
 
Stakeholders 
 
SBIRT Tools 
 
 
ACTIVITIES 
 
PARTICIPANTS 
 
SHORT 
TERM  
 
MEDIUM 
TERM  
 
LONG 
TERM  
EBP Guidelines 
 
SBIRT Training 
 
Implementation  
 
Consultation 
 
Providers 
 
Patients 
 
Administration 
 
1)CDC 
guideline 
implementati
on 
 
2)SBIRT 
implementati
on 
 
 
 
1)SBIRT 
adoption at 
multiple 
sites 
 
2)Better 
prescribing 
habits 
 
1)Prevent 
misuse/ 
abuse of 
opioids 
2)Prevention  
of OUD 
3)Decrease 
healthcare 
costs 
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APPENDIX E –Opioid Risk Tool (ORT) 
OPIOID RISK TOOL 
    Mark each Item Score      
Item Score box that applies         
     If Female           If Male 
1. Family History of Substance Abuse Alcohol [ ]    1   3 
      Illegal Drugs [ ]   2   3 
      Prescription Drugs [ ]  4   4 
2. Personal History of Substance Abuse Alcohol [ ]    3   3 
      Illegal Drugs [ ]   4   4 
      Prescription Drugs [ ]  5   5
  
3. Age (Mark box if 16 – 45) [ ]       1   1 
4. History of Preadolescent Sexual Abuse [ ]                 3   0 
5. Psychological Disease Attention Deficit [ ]     2   2 
Disorder, 
Obsessive Compulsive 
Disorder, 
Bipolar, 
Schizophrenia 
    Depression [ ]     1   1 
 
          
TOTAL –––––––––––– 
 
Total Score Risk Category 
Low Risk 0 – 3 
Moderate Risk 4 – 7 
High Risk > 8 
 
Reference: Webster LR. Predicting aberrant behaviors in opioid-treated patients: Preliminary 
validation of the opioid risk tool. Pain Medicine. 2005;6(6):432-442. Used with permission. 
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APPENDIX F – SBIRT Algorithm 
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